Luma Therapeutics Initiates Clinical Trial for People with Mild-to-Severe Psoriasis

MILLBRAE, CA – June 14, 2017 – Luma Therapeutics, Inc., a medical device company developing innovative technologies for inflammatory skin disease, announced today the initiation of a multi-center randomized study to demonstrate the safety and efficacy of the Luma Light System in treating psoriasis. This trial will build upon positive results from two previous feasibility studies using earlier versions of the Luma Light System.

Patients enrolled in the trial will treat their psoriasis at home with the Luma Therapeutics System of occlusive hydrogel patches, a light, and an app that controls the light. Narrowband UV-B light has been shown to decrease the immune response, and the occlusive hydrogel patches can reduce inflammation and decrease cell growth. The combination of these treatments may result in remission of psoriasis.

“We started Luma Therapeutics to empower people suffering from inflammatory skin disease,” said Evan Anderson, Founder and CEO of Luma Therapeutics, “and this trial is an important milestone as we plan to move forward to submit the Luma System to the US Federal Drug Administration for regulatory clearance this year.”

More information about the Luma Therapeutics System and the clinical trial can be found at

About Luma Therapeutics: Luma Therapeutics, Inc. is a medical device company based in Millbrae, CA. Founded in 2013, Luma Therapeutics is developing light therapy systems to improve inflammatory skin disease, starting with psoriasis.

Luma Therapeutics (
10 Rollins Rd, Suite 120, Millbrae, CA 94030
650-260-8245 –